The pharmaceutical industry flashes billion investments and “Novo Nordisk in Finland”

In Finland Effective pharmaceutical companies commit to more than double their investment in this decade. The condition is, inter alia, that the government would refrain from new drug savings and facilitate the scarcity of research staff in hospitals.

The Medicines Industry Association represented by a company on Friday the Minister of Finance Riikka to Purra (ps) The so -called growth promise of the industry.

Pharmaceutical companies invested more than EUR 460 million in Finland last year. Investments have doubled in a few years, and half of them focused on research and product development (R&D) and half of production last year.

CEO of the Pharmaceuticals Association Anne-Mari Estonia says that the industry is ready to increase the total investments of the pharmaceutical sector to one billion euros by 2030 if the operating environment remains stable.

The interest organization considers that doubling investments would help the Prime Minister Petteri Orpo (Kok) The Government of its Government Program will increase Finland’s R&D investments to 4 % of GDP.

“As Finland’s R&D investments come from the private sector, the business environment must be predictable. This means that there will be no unpredictable legislative changes and no continuation of the savings line, but would see that the conditions for growth are at hand,” says Virolainen.

The pharmaceutical industry In particular, the government’s drug savings are in particular. The government decided in the fall budget of 2023 and in the spring frame of 2024 on the cost of € 90 million for the cost of drug costs this year. The savings came as a surprise to the industry.

The aim of drug savings is to balance the state’s economy. Drug reimbursements are paid each year for nearly EUR 2 billion.

The government will meet in April in a mid -term, which is expected to focus on growth instead of additional savings. Riihene was based on the CEO of Varma’s Employment Pension Company Risto Murron The Growth Working Group led by recently left its final report.

“We need to get the cake raised before any of us can start demanding to give us more. We want to be involved in Finland’s economic growth,” says Virolainen.

Pharmaceutical Virolainen says that the additional investment euros for pharmaceutical companies would go especially for clinical drug studies.

The number of clinical drug surveys has fallen for years. There are currently about one hundred clinical drug studies in Finland, while the number was double in recent years.

According to the pharmaceutical industry, well -being areas would be interested in involved in drug studies funded by pharmaceutical companies. However, doctors and other staff are so overworked that there is no time for examinations.

“We constantly receive feedback from companies to want to do research in Finnish hospitals, but the resource problem is such that research cannot be taken,” says Virolainen.

Pharmaceutical The increase in investment in a billion euros would get Finland closer to the control countries Sweden and Denmark.

In Sweden, investments in R&D alone in 2022, according to EFPIA statistics for pharmaceutical companies, were EUR 1.1 billion and EUR 1.5 billion in the pharmaceutical industry in the famous pharmaceutical industry.

Novo Nordisk’s hit product of the Danish pharmaceutical leadership star is Ozempic, a diabetes drug used as a diet drug. It has been compared to the nokia miracle of Finland in the 1990s.

If the pharmaceutical industry implements its investment promise, would Finland have its own Ozempic?

“We already have a couple of such good drugs, but I can’t comment on what those medicines would be,” says Virolainen.